相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Louis de Mestier et al.
NEUROENDOCRINOLOGY (2020)
Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG
Matthew P. Thorpe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial
Edward Buitenwerf et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma
Dhaval Patel et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Clinical features, complications, and outcomes of exogenous and endogenous catecholamine-triggered Takotsubo syndrome: A systematic review and meta-analysis of 156 published cases
Shams Y-Hassan et al.
CLINICAL CARDIOLOGY (2020)
Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop
Patricia L. M. Dahia et al.
ENDOCRINE-RELATED CANCER (2020)
Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature
Anli Tong et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
Jacques W. M. Lenders et al.
JOURNAL OF HYPERTENSION (2020)
TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition
Aurelie Morin et al.
CELL REPORTS (2020)
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Aung Naing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas
Shams Y-Hassan et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin
Carl Christofer Juhlin et al.
ENDOCRINE PATHOLOGY (2020)
Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors
Divya Mamilla et al.
HUMAN PATHOLOGY (2020)
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
Camilo Jimenez et al.
CANCERS (2020)
MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives
Vincent Amodru et al.
ENDOCRINE (2020)
Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis
Sangwon Han et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management
Oksana Hamidi
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2019)
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
Madhav Prasad Yadav et al.
EJNMMI RESEARCH (2019)
The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas-A Meta-Analysis and Systematic Review of the Literature
Adam Stenman et al.
CANCERS (2019)
Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma
Jacob Kohlenberg et al.
CANCERS (2019)
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial
Grainne M. O'Kane et al.
BRITISH JOURNAL OF CANCER (2019)
Diffusion-weighted imaging (DWI) highlights SDHB-related tumours: A pilot study
Nicola Tufton et al.
CLINICAL ENDOCRINOLOGY (2019)
Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE
Wouter T. Zandee et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
David Taieb et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
A phase I clinical trial for [131I] meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
Hiroshi Wakabayashi et al.
SCIENTIFIC REPORTS (2019)
11C-hydroxy-ephedrine-PET/CT in the Diagnosis of Pheochromocytoma and Paraganglioma
Achyut Ram Vyakaranam et al.
CANCERS (2019)
Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE
Achyut Ram Vyakaranam et al.
CANCERS (2019)
Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study
Filip Ctvrtlik et al.
BIOMEDICAL PAPERS-OLOMOUC (2019)
'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'
Swayamjeet Satapathy et al.
CLINICAL ENDOCRINOLOGY (2019)
Pheochromocytoma and Paraganglioma
Hartmut P. H. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diagnostic Accuracy of Computed Tomography to Exclude Pheochromocytoma: A Systematic Review, Meta-analysis, and Cost Analysis
Edward Buitenwerf et al.
MAYO CLINIC PROCEEDINGS (2019)
Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior
Adam Stenman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma
Sylvie Job et al.
CLINICAL CANCER RESEARCH (2019)
CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma
Letizia Canu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery
Lucinda M. Gruber et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Daniel A. Pryma et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas
Laura Remacha et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2019)
Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome
Shams Y-Hassan et al.
ENDOCRINE (2019)
TERT structural rearrangements in metastatic pheochromocytomas
Trisha Dwight et al.
ENDOCRINE-RELATED CANCER (2018)
Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population
Abhishek Jha et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma
Richard B. Noto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center
Henrik Falhammar et al.
ENDOCRINE CONNECTIONS (2018)
68Ga-somatostatin receptor analogs and 18F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis
Ying Kan et al.
ACTA RADIOLOGICA (2018)
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma
Alfonso M. Ferrara et al.
ANTI-CANCER DRUGS (2018)
Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas
Alexandre Buffet et al.
CANCER RESEARCH (2018)
Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy
Irfan Jawed et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2018)
Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas
Matti L. Gild et al.
CLINICAL ENDOCRINOLOGY (2018)
Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan
Mitsuhide Naruse et al.
ENDOCRINE JOURNAL (2018)
Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study
Edward Buitenwerf et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
Ulrike Garske-Roman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer
Camilo Jimenez
FRONTIERS IN ENDOCRINOLOGY (2018)
CT and MRI of adrenal gland pathologies
Fuqin Wang et al.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY (2018)
Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center
Henrik Falhammar et al.
ENDOCRINE (2018)
Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma
Guillaume Gravel et al.
ENDOCRINE (2018)
Severe Cushing Syndrome Due to an ACTH-Producing Pheochromocytoma: A Case Presentation and Review of the Literature
Jenan N. Gabi et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2018)
Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma
Alejandro Roman-Gonzalez et al.
ANNALS OF SURGERY (2018)
External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma
William Breen et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas
Rodrigo A. Toledo et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
Grace Kong et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
Oksana Hamidi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas
Konstantinos Nastos et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas
Laura Remacha et al.
CLINICAL CANCER RESEARCH (2017)
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander et al.
CLINICAL CANCER RESEARCH (2017)
Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT, and MIBG SPECT/CT in the Evaluation of Suspected Primary Pheochromocytomas and Paragangliomas
Hongli Jing et al.
CLINICAL NUCLEAR MEDICINE (2017)
Frequency of Cushing's syndrome due to ACTH-secreting adrenal medullary lesions: a retrospective study over 10 years from a single center
Henrik Falhammar et al.
ENDOCRINE (2017)
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Lauren Fishbein et al.
CANCER CELL (2017)
Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases
Aurelien Archier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma
Ingo Janssen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Pheochromocytoma and Paraganglioma Diagnosis, Genetics, and Treatment
Colleen M. Kiernan et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2016)
68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
Chian A. Chang et al.
CANCER IMAGING (2016)
CLINICAL OUTCOMES IN ADRENAL INCIDENTALOMA: EXPERIENCE FROM ONE CENTER
Jekaterina Patrova et al.
ENDOCRINE PRACTICE (2015)
Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma
Sonali Thosani et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas-a retrospective cohort study
Hannah Yeomans et al.
BMC ENDOCRINE DISORDERS (2015)
The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors
Tiantian Liu et al.
ENDOCRINE-RELATED CANCER (2014)
Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma
Noriko Kimura et al.
ENDOCRINE-RELATED CANCER (2014)
Biochemical diagnosis of phaeochromocytoma and paraganglioma
A. van Berkel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
Julien Hadoux et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
Jacques W. M. Lenders et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features
Alberto Mazza et al.
ENDOCRINE (2014)
SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma
Eric Letouze et al.
CANCER CELL (2013)
Bone Metastases and Skeletal-Related Events in Patients With Malignant Pheochromocytoma and Sympathetic Paraganglioma
Montserrat Ayala-Ramirez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Imaging Work-Up for Screening of Paraganglioma and Pheochromocytoma in SDHx Mutation Carriers: A Multicenter Prospective Study from the PGL.EVA Investigators
Anne-Paule Gimenez-Roqueplo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids
Joakim Crona et al.
NEUROENDOCRINOLOGY (2013)
Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Camilo Jimenez et al.
CURRENT ONCOLOGY REPORTS (2013)
Phase 2 Study of Everolimus Monotherapy in Patients With Nonfunctioning Neuroendocrine Tumors or Pheochromocytomas/Paragangliomas
Do-Youn Oh et al.
CANCER (2012)
Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status
Graeme Eisenhofer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas
Montserrat Ayala-Ramirez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma
Nelly Burnichon et al.
HUMAN MOLECULAR GENETICS (2011)
68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours
Meeran Naji et al.
MOLECULAR IMAGING AND BIOLOGY (2011)
Radioiodinated Metaiodobenzylguanidine (MIBG): Radiochemistry, Biology, and Pharmacology
Shankar Vallabhajosula et al.
SEMINARS IN NUCLEAR MEDICINE (2011)
Comparison of High-Specific-Activity Ultratrace 123/131I-MIBG and Carrier-Added 123/131I-MIBG on Efficacy, Pharmacokinetics, and Tissue Distribution
John A. Barrett et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer
Herbert Chen et al.
PANCREAS (2010)
The Value of Immunoassays for Metanephrines in the Biochemical Diagnosis of Pheochromocytomas
N. Unger et al.
HORMONE AND METABOLIC RESEARCH (2009)
Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)
M. R. Druce et al.
HORMONE AND METABOLIC RESEARCH (2009)
Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma
Anthony M. Joshua et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma
Sara Gonias et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
Francien H. van Nederveen et al.
LANCET ONCOLOGY (2009)
Treatment of Malignant Pheochromocytoma/Paraganglioma With Cyclophosphamide, Vincristine, and Dacarbazine Recommendation From a 22-Year Follow-up of 18 Patients
Hui Huang et al.
CANCER (2008)
Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous
Frank J. Quayle et al.
SURGERY (2007)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
An analysis of the biochemical diagnosis of 66 pheochromocytomas
Michele d'Herbomez et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Genetic testing in pheochromocytoma or functional paraganglioma
L Amar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma
L Amar et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan
M Omura et al.
HYPERTENSION RESEARCH (2004)
Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients
JP Baguet et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms - A clinicopathologic and immunophenotypic study of 100 cases
LDR Thompson
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
分享论文
